Health ❯ Healthcare

Adverse Events

Drug Safety Vaccine Safety Treatment-Related Adverse Events Medication Safety Safety Profile Treatment Safety Clinical Outcomes Clinical Trials Treatment-Emergent Adverse Events Drug Side Effects

3 ARTICLES

3w ago

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

A prespecified statistical adjustment for on‑protocol crossover produced a significant survival advantage, a result that could shape first‑line treatment choices.

5 ARTICLES

last mo.

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

8 ARTICLES

last mo.

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

5 ARTICLES

3mo ago

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

7 ARTICLES

3mo ago

Brazil Suspends Butantan Single‑Dose Dengue Vaccine After Rare Severe Events

3 ARTICLES

3mo ago

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

4 ARTICLES

3mo ago

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

5 ARTICLES

8mo ago

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

5 ARTICLES

8mo ago

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

7 ARTICLES

9mo ago

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

7 ARTICLES

9mo ago

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

11 ARTICLES

10mo ago

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

8 ARTICLES

10mo ago

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

3 ARTICLES

10mo ago

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

3 ARTICLES

10mo ago

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

7 ARTICLES

10mo ago

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

5 ARTICLES

11mo ago

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Adverse Events

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Brazil Suspends Butantan Single‑Dose Dengue Vaccine After Rare Severe Events

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

Spyre Drug Meets Midstage Target in Ulcerative Colitis, Stock Rallies

PrimeC Shows Safety and Potential Benefit in ALS Phase 2b as FDA Authorizes Phase 3

Never miss stories about

Adverse Events

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Epcoritamab Added to R2 Yields Large Efficacy Gains in Relapsed Follicular Lymphoma

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

FDA Clears Padcev Plus Keytruda Regimens as Perioperative Option for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Never miss stories about

Adverse Events